Jury To Weigh Lost Profits In Neurontin Patent Fight

Law360 (April 6, 2011, 2:30 PM EDT) -- A New Jersey federal judge ruled Monday that a jury should decide whether Pfizer Inc. is entitled to lost profits in its long-running patent infringement case against several generics makers over epilepsy drug Neurontin.

Judge Faith S. Hochberg of the U.S. District Court for the District of New Jersey denied cross-motions for summary judgment on Pfizer's claim for lost profits caused by sales of generic products, finding that the issue should be left to the jury in a trial scheduled to start May 16.

Generics makers...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.